Top-News

Anixa Biosciences Aktie News

Aktie
WKN:  A2N6ZF ISIN:  US03528H1095 US-Symbol:  ANIX Branche:  Biotechnologie Land:  USA
4,07 €
+0,00 €
0,00%
07:11:37 Uhr
Depot/Watchlist
Marktkapitalisierung *
113,88 Mio. €
Streubesitz
78,02%
KGV
-11,80
Index-Zuordnung
-

Anixa Biosciences News

18.08.25 - PR Newswire
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial PR Newswire
12.08.25 - PR Newswire
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology PR Newswire
08.08.25 - PR Newswire
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference PR Newswire
04.08.25 - PR Newswire
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial PR Newswire
30.07.25 - PR Newswire
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology PR Newswire
24.07.25 - PR Newswire
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s PR Newswire
09.07.25 - IRW-Press
Anixa Biosciences meldet Erteilung eines weiteren US-Patents für die Impfstofftechnologie gegen Eierstockkrebs
SAN JOSE, Kalifornien, 9. Juli 2025 / IRW-Press / Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention ...
09.07.25 - PR Newswire
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology PR Newswire
23.06.25 - IRW-Press
Anixa Biosciences beginnt mit Verabreichung an die vierte Kohorte im Rahmen der klinischen Studie zur CAR-T-Therapie beim Ovarialkarzinom
Die Dosis der vierten Kohorte beträgt drei Millionen CAR-​positive Zellen - dreißigmal höher als die Dosis der ersten Kohorte SAN JOSE, Kalifornien, 23. Juni 2025 / IRW-Press / ...
23.06.25 - PR Newswire
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire
20.06.25 - IRW-Press
Anixa Biosciences veranstaltet am 26. Juni 2025 einen Webcast für Investoren
SAN JOSE, Kalifornien, 20. Juni 2025 / IRW-Press / Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention ...
20.06.25 - PR Newswire
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
Anixa Biosciences to Host an Investor Webcast on June 26, 2025 PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
10.06.25 - PR Newswire
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage PR Newswire
09.06.25 - IRW-Press
Anixa Biosciences wird beim Gynaecological Cancers Congress 2025 der ESMO ein wissenschaftliches Poster zur klinischen CAR-T-Studie beim Ovarialkarzinom präsentieren
SAN JOSE, Kalifornien, 9. Juni 2025 / IRW-Press / Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention ...
09.06.25 - PR Newswire
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 PR Newswire
03.06.25 - PR Newswire
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview PR Newswire
02.06.25 - IRW-Press
Anixa Biosciences meldet Abschluss der Aufnahme in Phase-1-Studie zu Brustkrebs-Impfstoff
SAN JOSE, Kalifornien, 2. Juni 2025 - Anixa Biosciences, Inc. (Anixa oder das Unternehmen) (NASDAQ: ANIX), ein auf die Krebstherapie und Krebsprävention spezialisiertes ...
02.06.25 - PR Newswire
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »